AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

Search

NVR Inc

Închisă

SectorConsumator ciclic

6,508.86 2.61

Rezumat

Modificarea prețului

24h

Curent

Minim

6343.44

Maxim

6589.83

Indicatori cheie

By Trading Economics

Venit

21M

364M

Vânzări

207M

2.7B

P/E

Medie Sector

15.037

33.36

EPS

121.54

Marjă de profit

13.412

Angajați

6,300

EBITDA

19M

476M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+27.24% upside

Dividende

By Dow Jones

Următoarele câștiguri

21 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.5B

19B

Deschiderea anterioară

6506.25

Închiderea anterioară

6508.86

Sentimentul știrilor

By Acuity

13%

87%

10 / 338 Clasament în Consumer cyclical

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

NVR Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

NVR Inc Așteptări

Obiectiv de preț

By TipRanks

27.24% sus

Prognoză pe 12 luni

Medie 8,104.4 USD  27.24%

Maxim 9,022 USD

Minim 7,100 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNVR Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

2

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

7007.57 / 7118.2Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

10 / 338 Clasament în Consumator ciclic

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre NVR Inc

NVR, Inc. operates as a homebuilder in the United States. The company operates through, Homebuilding and Mortgage Banking segments. It engages in the construction and sale of single-family detached homes, townhomes, and condominium buildings under the Ryan Homes, NVHomes, and Heartland Homes names. The company markets its Ryan Homes products to first-time and first-time move-up buyers; and NVHomes and Heartland Homes products to move-up and luxury buyers. It also provides various mortgage related services to its homebuilding customers, as well as brokers title insurance; performs title searches in connection with mortgage loan closings; and sells mortgage loans to investors in the secondary markets on a servicing released basis. The company primarily serves in Maryland, Virginia, West Virginia, Delaware, New Jersey, Eastern Pennsylvania, New York, Ohio, Western Pennsylvania, Indiana, Illinois, North Carolina, Georgia, South Carolina, Florida, Tennessee, and Washington, D.C. NVR, Inc. was founded in 1980 and is headquartered in Reston, Virginia.
help-icon Live chat